

Appln. No. 09/744,605
Amd. dated March 3, 2006
Reply to Office Action of December 6, 2005

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-16 (Cancelled).

17 (Currently amended). The method of claim ~~[[16]]~~ 19, wherein said interferon is selected from the group consisting of α -interferon, β -interferon and γ -interferon.

Claim 18 (Cancelled).

19 (Currently Amended). A method of inducing the death of ~~undesirable~~ leukemia or lymphoma cells, comprising administering to a patient in need thereof amounts of a) arsenic trioxide or a caspase inhibitor selected from the group consisting of zVAD and DEVD; and b) an interferon, effective to synergistically induce the death of leukemia or lymphoma cells.

Claims 20-28 (Cancelled).

29 (Previously presented). The method of claim 19, wherein said caspase inhibitor is zVAD.

30 (Previously presented). The method of claim 19, wherein said caspase inhibitor is DEVD.

Appln. No. 09/744,605
Amd. dated March 3, 2006
Reply to Office Action of December 6, 2005

Claims 31-33 (Cancelled).

34(New). A method of treating or inhibiting leukemia, comprising administering to a patient in need thereof synergistically effective amounts of a) arsenic trioxide or a caspase inhibitor selected from the group consisting of zVAD and DEVD and b) an interferon to treat or inhibit leukemia.

35(New). The method of claim 34, wherein the leukemia is acute promyelocytic leukemia.

36(New). The method of claim 34, wherein said interferon is selected from the group consisting of α -interferon, β -interferon and γ -interferon.

37(New). The method of claim 34, wherein said caspase inhibitor is zVAD.

38(New). The method of claim 34, wherein said caspase inhibitor is DEVD.